MRNA-LNPs brucella vaccine, expression vector and preparation method of mRNA-LNPs brucella vaccine

The mRNA-LNPs vaccine encoding BP26 and Omp25 proteins optimizes immune stimulation, addressing the limitations of current vaccines by inducing robust immune responses and effective protection against Brucella.

CN120305395APending Publication Date: 2025-07-15INNER MONGOLIA AUTONOMOUS REGION INT MONGOLIAN MEDICINE HOSPITAL INNER MONGOLIA AUTONOMOUS REGION MONGOLIAN MEDICINE RES INST
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202510551736.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-04-29
Publication Date
2025-07-15

AI Technical Summary

Technical Problem

The existing Brucella vaccine has limited protection capabilities and poses a risk of contagion, and requires the development of a more effective and safe vaccine.

Method used

Using mRNA-LNPs technology, mRNA-LNPs Brucella vaccine was prepared by mRNA encapsulation of outer membrane proteins BP26 and Omp 25, antigen sequence was optimized and in vitro transcription was performed to form mRNA with 5' capped and 3' Poly(A) tail structure, with an encapsulation concentration of 100 ug/mL.

Benefits of technology

It significantly increases the antibody titer, can stimulate a powerful immune response, induce Th1, Th2 or mixed Th-type reactions, and provides effective protection against Brucella.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120305395A_ABST
    Figure CN120305395A_ABST
Patent Text Reader

Abstract

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and particularly relates to an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. Background Art

[0002] Brucellosis is an animal-borne infectious disease caused by Brucella. This disease is transmitted to humans through the excreta of infected animals or by consuming food made from infected animals. High-risk groups include people living or traveling in disease-endemic areas (such as pastoral areas), as well as occupational groups exposed to Brucella, such as slaughterhouse workers, meat processors, and veterinarians. It is widely prevalent globally, especially in the Mediterranean region, Eastern Europe, Latin America, Africa, Asia, the Caribbean, and the Middle East.

[0003] Current Brucella vaccines mainly induce the immunodominance of outer membrane proteins, and the protective ability of attenuated vaccines or inactivated vaccines is limited. There is a need to develop effective vaccines with broad protective effects. Research has found that recombinant outer membrane protein BP26 and recombinant outer membrane protein Omp 25 activate B cells to produce a strong humoral immune response and activate T cells to produce related cellular immune responses. The results of mouse immunization experiments show that high titers of IgG, IgG1, and IgG2a can be produced. It can successfully induce Th1-type responses, Th2-type responses, or mixed Th-type responses, providing a solid immune basis for resisting Brucella.

[0004] In recent years, with the continuous in-depth development of immunology technology and the rapid development of genetic engineering technology, new vaccines such as DNA recombinant vaccines, synthetic peptide vaccines, and mRNA vaccines have emerged continuously. Among them, as a nucleic acid vaccine, mRNA vaccines can express any protein and can treat almost all protein-based diseases at the gene level. Compared with other traditional vaccines and DNA vaccine technologies, the synthesis of mRNA vaccines not only has a simple production process but also is inexpensive. At the same time, this artificially designed nucleic acid does not trigger the body's immune response, does not enter the cell nucleus, and has no risk of integrating into the genome, making it relatively safer.

[0005] Currently, the Brucella vaccines on the market are mainly inactivated or attenuated vaccines. The production time of attenuated vaccines is long, and their immunogenicity is limited. Attenuated live vaccines have a risk of infecting humans and pose potential risks.

[0006] LNPs: Lipid nanoparticles.

[0007] Luciferase: Luciferase.

[0008] Alum: Alum.

[0009] Protein: Protein.

[0010] Serum: Serum.

[0011] Day: Day.

[0012] Specific: Specificity.

[0013] Humanized Fc fragment: Fc SP: Signal peptide Summary of the Invention

[0014] The object of the present invention is to provide an mRNA-LNPs Brucella vaccine.

[0015] To solve the above problems, the technical solution of the present invention is: An mRNA-LNPs Brucella vaccine, comprising at least one of the mRNA of outer membrane protein BP26 and the mRNA of outer membrane protein Omp 25.

[0016] Further improvement, the nucleotide sequence of the mRNA of the outer membrane protein BP26 is the nucleotide sequence translated from the nucleotide sequence shown in SEQ NO1.

[0017] Further improvement, the nucleotide sequence of the mRNA of the outer membrane protein Omp 25 is the nucleotide sequence translated from the nucleotide sequence shown in SEQ NO2.

[0018] Further improvement, the final concentrations of the mRNA of the outer membrane protein BP26 and the mRNA of the outer membrane protein Omp 25 are both 100 ug / mL and are encapsulated by lipid nanoparticles.

[0019] An expression vector, the expression vector is a pIVT-UP vector containing the nucleotide sequence shown in SEQ NO1 or the nucleotide sequence shown in SEQ NO2.

[0020] A method for preparing an mRNA-LNPs Brucella vaccine, comprising the following steps: Respectively prepare expression vectors containing the nucleotide sequence shown in SEQ NO1 and the nucleotide shown in SEQ NO2, then transform the expression vectors into bacteria respectively, culture the bacteria and then extract the plasmids in the bacteria, then digest with enzymes to obtain a batch of the nucleotide sequence shown in SEQ NO1 and the nucleotide sequence shown in SEQ NO2, and then transcribe the nucleotide sequence shown in SEQ NO1 and the nucleotide sequence shown in SEQ NO2 into mRNA in vitro respectively, and the transcribed mRNA is the mRNA-LNPs Brucella vaccine.

[0021] For further improvement, when transcribing mRNA in vitro, 5'-capped mRNA is synthesized by in vitro transcription, and at the same time, a Poly(A) tail structure is added to the 3' end of the mRNA to obtain a structure with 5'-capping and 3'-PolyA addition.

[0022] Compared with the prior art, the present invention has the following advantages: The antigen sequence of the present invention has been optimized, and the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity. Compared with the Brucella vaccine prepared before sequence optimization, the antibody titer is significantly increased. The results of mouse immunization experiments show that it can produce high titers of IgG, IgG1, and IgG2a. It successfully induces Th1-type response, Th2-type response, or mixed Th-type response.

[0023] The mRNA Brucella vaccine prepared by the present invention has a significant protective effect on mice and can resist the infection of Brucella bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 The results of electrophoresis of two in vitro transcribed mRNAs, where 1 is (Omp25-Fc mRNA) and 2 is (BP26-Fc mRNA); Figure 2 It is an immunization flow chart; Figure 3 It is the result of ELISA for detecting specific IgG; Figure 4 It is the result of ELISA for detecting specific IgG1; Figure 5 It is the result diagram of ELISA for detecting specific IgG2a; Figure 6 It is the result diagram of ELISA for detecting IFN-γ and IL-4 in serum. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0025] Example 1 Construction of Recombinant Protein Vector The recombinant protein vector sequentially includes a signal peptide, an antigen, and a humanized Fc fragment from the N-terminus to the C-terminus.

[0026] The antigen is BP26 and Omp25, and corresponding recombinant proteins are obtained by recombining different antigens respectively.

[0027] According to the nucleotide sequences of the various recombinant proteins described above, they were synthesized by Suzhou Hongxun Biotechnology Co., Ltd. and ligated to the pIVTup vector respectively. The obtained recombinant vectors were named pIVTup-SP-BP26-Fc and pIVTup-SP-Omp25-Fc. These vectors were transformed, shaken in bacteria, and plasmids were extracted according to conventional experimental methods. The concentration of each plasmid was 1.0 μg / μL, and 2 kinds of pIVTup recombinant vectors were obtained.

[0028] In this application, the antigen sequences of BP26 and Omp25 were optimized.

[0029] The nucleotide sequence of BP26 is as shown in SEQ NO1, and the nucleotide sequence of Omp25 is as shown in SEQ NO1.

[0030] Example 2 In vitro transcription of mRNA (IVT mRNA) The DNA obtained in Example 1 was transcribed into mRNA in vitro. The specific method was carried out according to the method of in vitro transcription of mRNA described in Example 3 of the in vitro patent kit instructions. Using The HiScribe T7 ARCA mRNA kit (NEB), 5'-capped mRNA was synthesized by in vitro transcription, and at the same time, a Poly(A) tail structure was added to the 3' end of the mRNA to obtain a 5'-capped and 3'-tailed (PolyA) structure. The concentration of the in vitro transcribed mRNA was measured and adjusted to 2 μg / μL, and it was stored at -20 °C for later use.

[0031] The mRNA was placed in a 70 °C water bath for 10 min, placed on ice for 3 min, electrophoresed in a urea acrylamide gel, electrophoresed at a constant voltage of 100 V for 30 min, and photographed with a gel imager to verify the size and integrity of the mRNA.

[0032] The results are as Figure 1 shown. The mRNA transcribed in vitro from 2 kinds of linearized pIVT-UP-SP-Omp25-Fc and pIVT-UP-SP-BP26-Fc recombinant vectors was electrophoresed in a urea acrylamide gel, and the obtained mRNA was consistent with the designed nucleotide size.

[0033] Example 3 Immunization program of the vaccine The overall immunization process is as Figure 2As shown in the figure. It is divided into 6 groups, among which two groups are control groups (Luciferase mRNA-LNPs group and placebo control alum group), two groups are mRNA-LNPs groups (Omp25-Fc mRNA-LNPs group and BP26-Fc mRNA-LNPs group), and two groups are protein vaccine groups (Omp25 protein + alum group and BP26 protein + alum group). Mice were immunized intravenously for a total of three immunizations (primary and 2 boosters), with a 14-day interval between each immunization.

[0034] Grouping of mouse immunization experiments Example 4 ELISA detection The levels of specific IgG, IgG1, and IgG2a antibodies against Omp25-Fc, BP26-Fc, Omp25, and BP26 proteins in serum samples on the 14th, 28th, and 42nd days after immunization were detected by the double antibody sandwich ELISA method respectively. The results are shown in Figure 3 、 Figure 4 and Figure 5 respectively (T test, *: p < 0.05).

[0035] The levels of IL-4 and IFN-γ cytokines in serum samples on the 14th, 28th, and 42nd days after immunization were detected by the double antibody sandwich ELISA method respectively. The results are shown in Figure 6 respectively (T test, *: p < 0.05).

[0036] The above results indicate that the present invention can produce high titers of IgG, IgG1, and IgG2a. It can successfully induce Th1-type response, Th2-type response, or mixed Th-type response.

[0037] The above embodiments are merely a specific implementation manner of the present invention and do not limit the present invention. Any simple improvement and replacement thereof are within the protection scope of the present invention.

Claims

1. An mRNA-LNPs Brucella vaccine, characterized in that, including at least one of the mRNA of outer membrane protein BP26 and the mRNA of outer membrane protein Omp 25; the nucleotide sequence of the mRNA of the outer membrane protein BP26 is the nucleotide sequence obtained by translating the nucleotide sequence shown in SEQ NO1; the nucleotide sequence of the mRNA of the outer membrane protein Omp 25 is the nucleotide sequence obtained by translating the nucleotide sequence shown in SEQ NO2.

2. The mRNA-LNPs Brucella vaccine according to claim 1, characterized in that, The final concentrations of the mRNA of the outer membrane protein BP26 and the mRNA of the outer membrane protein Omp 25 are both 100 μg / mL and are encapsulated by lipid nanoparticles.

3. An expression vector, characterized in that, The expression vector is the pIVT-UP vector containing the nucleotide sequence shown in SEQ NO1 or the nucleotide sequence shown in SEQ NO2.

4. A method for preparing an mRNA-LNPs Brucella vaccine, characterized in that, comprising the following steps: Respectively prepare expression vectors containing the nucleotide sequence shown in SEQ NO1 and the nucleotide shown in SEQ NO2, then transform the expression vectors into bacteria respectively, culture the bacteria and then extract the plasmids in the bacteria, and then digest with enzymes to obtain a batch of the nucleotide sequence shown in SEQ NO1 and the nucleotide shown in SEQ NO2. Then, transcribe the nucleotide sequence shown in SEQ NO1 and the nucleotide sequence shown in SEQ NO2 into mRNA in vitro respectively, and the transcribed mRNA is the mRNA-LNPs Brucella vaccine.

5. The preparation method of the mRNA-LNPs Brucella vaccine according to claim 4, characterized in that, When transcribing mRNA in vitro, synthesize 5'-capped mRNA in vitro, and at the same time add a Poly(A) tail structure to the 3' end of the mRNA to obtain a 5'-capped and 3'-PolyA structure.

Citation Information

Cited By

  • Mixed vaccine for expressing brucella multiple antigens as well as preparation method and application of mixed vaccine

    CN120478610A

  • Brucella vaccine as well as preparation method and application thereof

    CN121337968A